Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

ConclusionsThis case and the review of current data confirm the benefit of BRAF inhibition in BRAF-mutated ATC, limited by acquired resistance to targeted therapy.
Source: Thyroid Research - Category: Endocrinology Source Type: research